About Madrigal Pharmaceuticals (NASDAQ:MDGL)
Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-55.2642276422764
Forward P/E Ratio-52.90
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$3.15 per share
Price / Book43.16
Return on Equity-65.22%
Return on Assets-57.35%
Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions
What is Madrigal Pharmaceuticals' stock symbol?
Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How were Madrigal Pharmaceuticals' earnings last quarter?
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) announced its earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.11. View Madrigal Pharmaceuticals' Earnings History.
Where is Madrigal Pharmaceuticals' stock going? Where will Madrigal Pharmaceuticals' stock price be in 2018?
4 brokerages have issued twelve-month price objectives for Madrigal Pharmaceuticals' shares. Their predictions range from $125.00 to $210.00. On average, they anticipate Madrigal Pharmaceuticals' share price to reach $166.50 in the next year. View Analyst Ratings for Madrigal Pharmaceuticals.
Who are some of Madrigal Pharmaceuticals' key competitors?
Some companies that are related to Madrigal Pharmaceuticals include Agios Pharmaceuticals (AGIO), Array BioPharma (ARRY), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Auspex Pharmaceuticals (ASPX), Loxo Oncology (LOXO), AnaptysBio (ANAB), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Clovis Oncology (CLVS), Ultragenyx Pharmaceutical (RARE), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Ascendis Pharma A/S (ASND), Myokardia (MYOK), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN) and Sangamo Therapeutics (SGMO).
Who are Madrigal Pharmaceuticals' key executives?
Madrigal Pharmaceuticals' management team includes the folowing people:
- Paul A. Friedman M.D., Chairman of the Board, Chief Executive Officer (Age 74)
- Rebecca A. Taub M.D., Founder, Chief Medical Officer, Executive Vice President, Research & Development and Director (Age 65)
- Marc R. Schneebaum, Chief Financial Officer, Senior Vice President (Age 63)
- Frederick B. Craves Ph.D., Lead Independent Director (Age 70)
- Kenneth M. Bate, Independent Director (Age 66)
- Keith R. Gollust, Independent Director (Age 71)
- Richard S. Levy M.D., Independent Director (Age 59)
- David V. Milligan Ph.D., Independent Director (Age 76)
Who owns Madrigal Pharmaceuticals stock?
Madrigal Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (2.72%), Rock Springs Capital Management LP (2.44%), BlackRock Inc. (1.50%), Victory Capital Management Inc. (1.46%), Jennison Associates LLC (1.46%) and Perceptive Advisors LLC (1.35%). View Institutional Ownership Trends for Madrigal Pharmaceuticals.
Who sold Madrigal Pharmaceuticals stock? Who is selling Madrigal Pharmaceuticals stock?
Who bought Madrigal Pharmaceuticals stock? Who is buying Madrigal Pharmaceuticals stock?
Madrigal Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Jennison Associates LLC, Perceptive Advisors LLC, Victory Capital Management Inc., Bogle Investment Management L P DE, Rock Springs Capital Management LP, EAM Investors LLC and Ascend Capital LLC. View Insider Buying and Selling for Madrigal Pharmaceuticals.
How do I buy Madrigal Pharmaceuticals stock?
Shares of Madrigal Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Madrigal Pharmaceuticals' stock price today?
One share of Madrigal Pharmaceuticals stock can currently be purchased for approximately $135.95.
How big of a company is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a market capitalization of $1.89 billion. The biopharmaceutical company earns $-26,380,000.00 in net income (profit) each year or ($2.46) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.
How can I contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' mailing address is 200 Barr Harbor Dr Ste 400, CONSHOHOCKEN, PA 19428-2978, United States. The biopharmaceutical company can be reached via phone at +1-404-3809263 or via email at [email protected]
MarketBeat Community Rating for Madrigal Pharmaceuticals (MDGL)MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings History and Estimates Chart
Madrigal Pharmaceuticals (NASDAQ MDGL) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings Estimates
Current Year EPS Consensus Estimate: $-2.57 EPS
Next Year EPS Consensus Estimate: $-3.24 EPS
Dividend History for Madrigal Pharmaceuticals (NASDAQ:MDGL)
No dividend announcements for this company have been tracked by MarketBeat.com
Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 66.40%
Institutional Ownership Percentage: 27.13%
Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/23/2017||Richard S Levy||Director||Buy||2,000||$16.12||$32,240.00||7,200|| |
|8/22/2017||Richard S Levy||Director||Buy||3,550||$16.12||$57,226.00||3,640|| |
|8/21/2017||Richard S Levy||Director||Buy||3,550||$15.88||$56,374.00||900|| |
|12/14/2015||Keith R Gollust||Director||Sell||600,000||$0.35||$210,000.00||401,764|| |
|12/9/2015||Keith R Gollust||Director||Sell||745,892||$0.38||$283,438.96||401,764|| |
|12/8/2015||Bruce Kovner||Director||Sell||1,523,346||$0.37||$563,638.02||3,092,677|| |
|12/3/2015||Bruce Kovner||Director||Sell||1,430,753||$0.43||$615,223.79||3,092,677|| |
|11/30/2015||Bruce Kovner||Director||Sell||3,078,820||$0.48||$1,477,833.60||3,092,677|| |
|11/24/2015||Bruce Kovner||Director||Sell||1,173,582||$0.44||$516,376.08||3,092,677|| |
|11/20/2015||Bruce Kovner||Director||Sell||1,513,088||$0.49||$741,413.12||3,092,677|| |
|11/17/2015||Bruce Kovner||Director||Sell||1,223,936||$0.43||$526,292.48||3,092,677|| |
|11/12/2015||Bruce Kovner||Director||Sell||5,436,673||$0.55||$2,990,170.15||3,092,677|| |
|11/10/2015||Keith R Gollust||Director||Sell||188,322||$0.55||$103,577.10||401,764|| |
|4/6/2015||Robert N Wilson||Director||Buy||50,000||$1.75||$87,500.00|| |
|9/30/2014||Bruce Kovner||Director||Buy||300,000||$3.08||$924,000.00|| |
|4/11/2014||Bruce Kovner||Director||Buy||1,250,000||$4.01||$5,012,500.00||3,048,666|| |
|11/13/2013||Bruce Kovner||Director||Buy||5,000,000||$3.75||$18,750,000.00||6,130,330|| |
|11/13/2013||Safi Bahcall||CEO||Buy||20,000||$3.75||$75,000.00||2,053,135|| |
|6/28/2013||Safi R Bahcall||CEO||Buy||10,000||$5.03||$50,300.00|| |
|6/27/2013||Bruce Kovner||Director||Buy||150,000||$4.71||$706,500.00|| |
|6/26/2013||Bruce Kovner||Director||Buy||500,000||$4.53||$2,265,000.00|| |
|6/21/2013||Bruce Kovner||Director||Buy||250,000||$4.39||$1,097,500.00|| |
|6/21/2013||Safi R Bahcall||CEO||Buy||20,000||$4.12||$82,400.00|| |
|6/18/2013||Bruce Kovner||Director||Buy||200,000||$4.00||$800,000.00|| |
|6/14/2013||Safi R Bahcall||CEO||Buy||10,000||$4.06||$40,600.00|| |
|6/6/2013||Bruce Kovner||Director||Buy||2,000,000||$4.64||$9,280,000.00|| |
|6/6/2013||Safi R Bahcall||CEO||Buy||10,000||$4.04||$40,400.00|| |
|6/5/2013||Vojo Vukovic||SVP||Buy||10,000||$4.58||$45,800.00|| |
|6/4/2013||Robert N Wilson||Director||Buy||10,000||$5.00||$50,000.00|| |
|11/14/2012||Bruce Kovner||Director||Buy||37,700||$6.91||$260,507.00|| |
|11/12/2012||Safi R Bahcall||CEO||Buy||10,000||$7.12||$71,200.00|| |
Madrigal Pharmaceuticals (NASDAQ MDGL) News Headlines
|Zacks: Brokerages Expect Madrigal Pharmaceuticals Inc (MDGL) Will Announce Earnings of -$0.68 Per Share|
www.americanbankingnews.com - February 15 at 1:24 PM
|Madrigal Pharmaceuticals (MDGL) PT Raised to $210.00|
www.americanbankingnews.com - February 9 at 10:36 PM
|Here’s What’s Moving Teva Pharmaceutical Industries And Madrigal Pharmaceuticals|
finance.yahoo.com - February 9 at 9:39 AM
|Madrigal Pharmaceuticals' (MDGL) Outperform Rating Reiterated at Evercore ISI|
www.americanbankingnews.com - February 8 at 11:18 AM
|Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)|
finance.yahoo.com - February 8 at 8:28 AM
|Madrigal Pharmaceuticals Inc (MDGL) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - February 8 at 1:32 AM
|Madrigal Pharmaceuticals (MDGL) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - February 4 at 6:22 AM
|Blog Exposure - Madrigal Pharma Declares Acceptance Of MGL-3196 Abstract for Main Plenary Presentation at International Liver Congress 2018|
finance.yahoo.com - February 1 at 9:43 AM
|Madrigal Pharma (MDGL) Reports Acceptance of MGL-3196 Abstract for a Main Plenary Presentation|
www.streetinsider.com - January 30 at 10:14 AM
|Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018|
finance.yahoo.com - January 30 at 10:14 AM
|-$0.69 EPS Expected for Madrigal Pharmaceuticals Inc (MDGL) This Quarter|
www.americanbankingnews.com - January 29 at 9:22 AM
|3 Stocks That Turned $5,000 Into at Least $23,000 in Just 12 Months|
finance.yahoo.com - January 23 at 9:33 AM
|Madrigal Pharmaceuticals (MDGL) Upgraded by BidaskClub to Strong-Buy|
www.americanbankingnews.com - January 20 at 9:48 AM
|Madrigal Pharmaceuticals (MDGL) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 9 at 6:08 AM
|5 Top Multibagger Stocks to Buy in 2018 - Nasdaq|
www.nasdaq.com - January 2 at 11:15 PM
|5 Top Multibagger Stocks to Buy in 2018|
finance.yahoo.com - January 2 at 9:42 AM
|Madrigal Pharmaceuticals (MDGL) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - December 24 at 12:26 AM
|Madrigal Pharmaceuticals: Elucidating The Upcoming Binary Event ... - Seeking Alpha|
seekingalpha.com - December 21 at 9:48 AM
|Madrigal Pharmaceuticals: Buy The Secondary - Seeking Alpha - Seeking Alpha|
seekingalpha.com - December 21 at 9:48 AM
|Montco biopharm seeking to raise $125M|
www.bizjournals.com - December 20 at 5:03 PM
|Madrigal Pharmaceuticals Inc (MDGL) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - December 20 at 3:22 AM
|Madrigal Pharmaceuticals Prices Public Offering of Common Stock|
finance.yahoo.com - December 19 at 9:49 AM
|Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - December 18 at 10:05 AM
|Madrigal Pharmaceuticals (MDGL) Price Target Raised to $170.00 at Roth Capital|
www.americanbankingnews.com - December 11 at 5:46 PM
|Madrigal Pharmaceuticals, Inc. (MDGL) Expected to Announce Earnings of -$0.69 Per Share|
www.americanbankingnews.com - December 9 at 8:04 AM
|Madrigal Pharmaceuticals (MDGL) Price Target Raised to $140.00|
www.americanbankingnews.com - December 7 at 5:40 PM
|Multi-Billion Dollar Global Medical Device Industry Led by Cardiovascular Monitoring Devices|
www.prnewswire.com - December 7 at 10:01 AM
|Today’s Research Reports on Stocks to Watch: Madrigal Pharmaceuticals and VistaGen Therapeutics|
finance.yahoo.com - December 7 at 10:01 AM
|Here's Why Biotricity (BTCY) Could Make A Similar Move to Madrigal (MDGL) and Digital Power Corp (DPW)|
finance.yahoo.com - December 7 at 10:01 AM
|Mid-Afternoon Market Update: Vera Bradley Rises On Earnings Beat; Fred's Shares Plunge - Nasdaq|
www.nasdaq.com - December 6 at 5:08 PM
|Why Madrigal Pharmaceuticals Stock Is On Fire Today|
finance.yahoo.com - December 6 at 5:08 PM
|Why Brown-Forman, H&R Block, and Madrigal Pharmaceuticals Jumped Today|
finance.yahoo.com - December 6 at 5:08 PM
|Madrigal Pharmaceuticals (MDGL) PT Raised to $125.00|
www.americanbankingnews.com - December 6 at 4:22 PM
|Madrigal Pharmaceuticals (MDGL) Given New $105.00 Price Target at HC Wainwright|
www.americanbankingnews.com - December 6 at 12:40 PM
|Madrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High On Study Results - Nasdaq|
www.nasdaq.com - December 6 at 9:56 AM
|Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial|
finance.yahoo.com - December 6 at 9:56 AM
|Roth Capital Analysts Give Madrigal Pharmaceuticals (MDGL) a $82.00 Price Target|
www.americanbankingnews.com - November 30 at 11:22 AM
|Madrigal Pharmaceuticals (MDGL) Earns Buy Rating from Analysts at HC Wainwright|
www.americanbankingnews.com - November 29 at 8:12 PM
|Benzinga's Top Upgrades, Downgrades For November 29, 2017 - Benzinga|
www.benzinga.com - November 29 at 9:52 AM
|Breaking Down Madrigal Pharmaceuticals Inc’s (MDGL) Ownership Structure|
finance.yahoo.com - November 23 at 6:24 AM
|Zacks: Brokerages Anticipate Madrigal Pharmaceuticals, Inc. (MDGL) Will Announce Earnings of -$0.65 Per Share|
www.americanbankingnews.com - November 21 at 9:24 AM
|Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results|
finance.yahoo.com - November 12 at 6:01 AM
|Madrigal Pharmaceuticals, Inc. (MDGL) Announces Earnings Results, Beats Estimates By $0.11 EPS|
www.americanbankingnews.com - November 10 at 6:44 PM
|-$0.84 Earnings Per Share Expected for Madrigal Pharmaceuticals, Inc. (MDGL) This Quarter|
www.americanbankingnews.com - October 31 at 9:14 PM
|Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting|
finance.yahoo.com - October 24 at 1:16 AM
|Madrigal Pharmaceuticals, Inc. (MDGL) Research Coverage Started at Roth Capital|
www.americanbankingnews.com - October 19 at 11:44 AM
|Madrigal Pharmaceuticals, Inc. (MDGL) PT Raised to $63.00|
www.americanbankingnews.com - October 13 at 8:22 AM
|Analyzing Madrigal Pharmaceuticals (MDGL) and Its Peers|
www.americanbankingnews.com - September 24 at 10:20 AM
|3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? - Motley Fool|
www.fool.com - September 24 at 1:10 AM
|Madrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High For The Year|
www.nasdaq.com - September 23 at 8:06 AM
Madrigal Pharmaceuticals (NASDAQ:MDGL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Madrigal Pharmaceuticals (NASDAQ:MDGL) Income Statement, Balance Sheet and Cash Flow Statement
Madrigal Pharmaceuticals (NASDAQ MDGL) Stock Chart for Tuesday, February, 20, 2018